Haemonetics Corp (NYSE: HAE) has a higher price-to-earnings ratio of 38.74x compared to its average ratio. HAE has 36-month beta value of 0.34. Analysts have mixed views on the stock, with 1 analysts rating it as a “buy,” 2 as “overweight,” 5 as “hold,” and 1 as “sell.”
The public float for HAE is 50.61M, and currently, short sellers hold a 10.40% ratio of that float. The average trading volume of HAE on November 07, 2024 was 616.64K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
HAE) stock’s latest price update
Haemonetics Corp (NYSE: HAE)’s stock price has soared by 10.64 in relation to previous closing price of 78.16. Nevertheless, the company has seen a gain of 21.53% in its stock price over the last five trading days. zacks.com reported 2024-11-07 that The headline numbers for Haemonetics (HAE) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
HAE’s Market Performance
Haemonetics Corp (HAE) has experienced a 21.53% rise in stock performance for the past week, with a 13.63% rise in the past month, and a 12.27% rise in the past quarter. The volatility ratio for the week is 3.02%, and the volatility levels for the past 30 days are at 2.53% for HAE. The simple moving average for the last 20 days is 15.02% for HAE’s stock, with a simple moving average of 6.17% for the last 200 days.
Analysts’ Opinion of HAE
Many brokerage firms have already submitted their reports for HAE stocks, with CL King repeating the rating for HAE by listing it as a “Buy.” The predicted price for HAE in the upcoming period, according to CL King is $116 based on the research report published on September 13, 2024 of the current year 2024.
BofA Securities, on the other hand, stated in their research note that they expect to see HAE reach a price target of $85. The rating they have provided for HAE stocks is “Neutral” according to the report published on September 11th, 2024.
BTIG Research gave a rating of “Buy” to HAE, setting the target price at $112 in the report published on September 10th of the current year.
HAE Trading at 14.32% from the 50-Day Moving Average
After a stumble in the market that brought HAE to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -11.73% of loss for the given period.
Volatility was left at 2.53%, however, over the last 30 days, the volatility rate increased by 3.02%, as shares surge +15.69% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +14.72% upper at present.
During the last 5 trading sessions, HAE rose by +21.04%, which changed the moving average for the period of 200-days by +5.32% in comparison to the 20-day moving average, which settled at $75.17. In addition, Haemonetics Corp saw 1.13% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at HAE starting from Strong Stewart W, who sale 4,312 shares at the price of $91.15 back on Jul 26 ’24. After this action, Strong Stewart W now owns 18,196 shares of Haemonetics Corp, valued at $393,039 using the latest closing price.
Strong Stewart W, the Officer of Haemonetics Corp, proposed sale 4,312 shares at $91.15 during a trade that took place back on Jul 26 ’24, which means that Strong Stewart W is holding shares at $393,039 based on the most recent closing price.
Stock Fundamentals for HAE
Current profitability levels for the company are sitting at:
- 0.13 for the present operating margin
- 0.51 for the gross margin
The net margin for Haemonetics Corp stands at 0.09. The total capital return value is set at 0.08. Equity return is now at value 12.98, with 5.10 for asset returns.
Based on Haemonetics Corp (HAE), the company’s capital structure generated 0.57 points at debt to capital in total, while cash flow to debt ratio is standing at 0.11. The debt to equity ratio resting at 1.35. The interest coverage ratio of the stock is 9.88.
Currently, EBITDA for the company is 305.35 million with net debt to EBITDA at 3.2. When we switch over and look at the enterprise to sales, we see a ratio of 3.98. The receivables turnover for the company is 6.62for trailing twelve months and the total asset turnover is 0.52. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.76.
Conclusion
To put it simply, Haemonetics Corp (HAE) has had a better performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
